Corona pandemic: J & J shares go out of trading: Johnson & Johnson earns less with rising sales | message

In the fight against the corona pandemic, the US company announced that it was making good progress with its vaccine candidate when it presented its business figures.

Thanks to good business with pharmaceuticals, revenues climbed 8.3 percent to 22.5 billion US dollars in the final quarter, as the pharmaceutical and consumer goods manufacturer announced. The net profit collapsed against it by more than half to 1.74 billion or 0.65 dollars per share. Adjusted, the company made $ 1.86 per share.

Analysts had expected sales in the three months only at $ 21.66 billion. Adjusted earnings per share were seen at $ 1.82.

For the new year as a whole, Johnson & Johnson expects sales of 90.5 billion to 91.7 billion dollars. In the past year, the US group had earned a total of $ 82.6 billion. Adjusted earnings per share should be between $ 9.40 to $ 9.60.

Ultimately, J&J stock on the NYSE rose 5.11 percent to $ 164.91.

NEW YORK (Dow Jones)

Image sources: josefkubes / Shutterstock.com